Jul 17, 2023 7:00am EDT Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
Jun 29, 2023 7:00am EDT Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
Jun 13, 2023 7:00am EDT Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
Jun 02, 2023 7:00am EDT Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
Jun 01, 2023 7:00am EDT Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
May 30, 2023 7:00am EDT Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
May 15, 2023 7:00am EDT Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
May 09, 2023 7:00am EDT Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
May 02, 2023 7:00am EDT Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
